Atika Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Atika Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-165,000	Closed	-$2.24M	–	82
2019 Q1	$2.24M	Buy	+165,000	New	+$2.02M	0.46%	64
2018 Q2	–	Sell	-100,000	Closed	-$1.5M	–	98
2018 Q1	$1.5M	Buy	+100,000	New	+$1.52M	0.52%	61
2015 Q4	–	Sell	-207,300	Closed	-$2.9M	–	60
2015 Q3	$2.9M	Buy	207,300 +22,900	+12%	+$359K	1.42%	29
2015 Q2	$2.61M	Buy	184,400 +21,400	+13%	+$257K	1.17%	37
2015 Q1	$1.77M	Sell	163,000 -37,000	-19%	-$326K	1.18%	41
2014 Q4	$1.66M	Buy	200,000 +70,000	+54%	+$480K	1.22%	34
2014 Q3	$774K	Buy	+130,000	New	+$681K	0.6%	55

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Atika Capital Management's FOLD Position: Q2 2019 in Review

Atika Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 165,000 shares — an estimated $2.24M sold.

Atika Capital Management first reported a position in FOLD in Q3 2014 and held it in 7 quarters. The position peaked at $2.9M in Q3 2015. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

Atika Capital Management reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
Atika Capital Management sold 165,000 Amicus Therapeutics shares in Q2 2019, an estimated $2.24M.
Atika Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 7 quarters.
Atika Capital Management's Amicus Therapeutics position peaked at $2.9M in Q3 2015.
206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Atika Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.